1. Home
  2. VPG vs TSHA Comparison

VPG vs TSHA Comparison

Compare VPG & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vishay Precision Group Inc.

VPG

Vishay Precision Group Inc.

HOLD

Current Price

$92.67

Market Cap

1.4B

Sector

Technology

ML Signal

HOLD

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

HOLD

Current Price

$5.82

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VPG
TSHA
Founded
2009
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.7B
IPO Year
2010
2020

Fundamental Metrics

Financial Performance
Metric
VPG
TSHA
Price
$92.67
$5.82
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
8
Target Price
$53.50
$11.63
AVG Volume (30 Days)
452.9K
2.9M
Earning Date
05-12-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
5.56
EPS
N/A
N/A
Revenue
$307,202,000.00
$9,773,000.00
Revenue This Year
$7.21
N/A
Revenue Next Year
$6.92
$1,152.42
P/E Ratio
N/A
N/A
Revenue Growth
0.22
17.28
52 Week Low
$25.58
$2.63
52 Week High
$151.78
$7.30

Technical Indicators

Market Signals
Indicator
VPG
TSHA
Relative Strength Index (RSI) 40.81 47.23
Support Level $37.49 $5.28
Resistance Level $150.08 $6.01
Average True Range (ATR) 8.14 0.39
MACD -1.60 0.00
Stochastic Oscillator 39.83 48.48

Price Performance

Historical Comparison
VPG
TSHA

About VPG Vishay Precision Group Inc.

Vishay Precision Group Inc manufactures and markets sensors and sensor-based measurement systems, as well as specialty resistors and strain gages based on proprietary technology. The company provides precision products and solutions, many of which are designed-in by customers, specializing in the growing markets of stress, force, weight, pressure, and current measurements. The company reports in three product segments: Sensors segment, Weighing Solutions segment, and Measurement Systems segment. It has a business presence in the United States and other countries. It generates the maximum of its revenue from the United States.

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

Share on Social Networks: